Neither word has anything to do with money -- at least not yet. On June 2, Intellia Therapeutics' (NTLA -0.96%) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement. But to the ears of other investors, the same two words imply a risk they'd rather not think about. Let's dive in and ...